NorthWest Biotherapeutics Inc (NWBO)

[froggie77]

"The average overall survival of the 20 patients in the trial was substantially longer than we would expect for patients receiving standard treatment," Dr. Parney says. "In addition, about 20% of patients in the study survived from four to five years, which is quite unusual in glioblastoma."

The vaccine is based on dendritic cells taken from an individual patient, enhanced in the laboratory and then combined with tumor proteins from a Mayo Clinic library of clinical grade brain tumor cell lines. A larger study is planned in patients with newly diagnosed glioblastoma. Dr. Parney notes that a separate trial of the vaccine in patients with recurrent glioblastoma, already underway, has also had encouraging early results.“

Found this from June of 2020, sounds so similar - yet slightly different than the DC-Vax platform. Similar (anticipated) ‘results’ too. Any thoughts?

https://www.mayoclinic.org/medical-professionals/neurology-neurosurgery/news/new-approaches-to-immunotherapy-for-glioblastoma/mac-20488153